Brexpiprazole: another multipurpose antipsychotic drug?

Area of Science:

• Pharmacology
• Neuroscience
• Drug Development

Background:

• Brexpiprazole (OPC-34712) is a novel compound structurally related to aripiprazole.
• It represents a new class of pharmacological agents with potential for diverse therapeutic applications.

Purpose of the Study:

• To introduce brexpiprazole as a novel molecular compound.
• To highlight its current review status for schizophrenia and major depressive disorder.
• To outline ongoing clinical investigations for other neurological and psychiatric conditions.

Main Methods:

• Chemical and structural analysis comparing brexpiprazole to aripiprazole.
• Review of ongoing and planned clinical trials for various indications.
• Assessment of brexpiprazole's potential for multipurpose pharmacological uses.

Main Results:

• Brexpiprazole is chemically and structurally similar to aripiprazole.
• The drug is under FDA review for schizophrenia monotherapy and as an adjunct for major depressive disorder.
• Clinical trials are exploring its efficacy in attention-deficit/hyperactivity disorder, posttraumatic stress disorder, and agitation in Alzheimer's dementia.

Conclusions:

• Brexpiprazole demonstrates significant therapeutic potential across multiple central nervous system disorders.
• Its development highlights the translation of pharmacological diversity into versatile clinical applications.
• Further research is warranted to fully elucidate its efficacy and safety profile in diverse patient populations.